Havrix Junior (Algeldrate, Hepatitis A Virus Antigen (Inactivated))

Havrix Junior is indicated for the prevention of hepatitis A infection in children and for active immunization against hepatitis A virus.

• Primary prophylaxis of hepatitis A in children aged 1‑2 years.
• Boosting immunity in children who have previously received a hepatitis A vaccine.
• Use in outbreak settings to quickly protect susceptible pediatric populations.
• Administration as part of routine childhood immunization schedules in regions where hepatitis A is endemic.
• Co-administration with other pediatric vaccines when recommended by health authorities.

The safety profile of Havrix Junior reflects the typical reactions observed with inactivated viral vaccines.

Common

• Mild pain, redness, or swelling at the injection site.
• Low‑grade fever.
• Headache or fatigue.
• Nausea or mild gastrointestinal discomfort.
• Mild rash or urticaria.

Serious

• Severe allergic reaction (anaphylaxis).
• High fever lasting more than 48 hours.
• Neurological symptoms such as seizures.
• Persistent joint pain or swelling.
• Guillain‑Barré syndrome (rare).
• Other severe systemic reactions requiring medical attention.

Before administering Havrix Junior, healthcare providers should review the following precautions and warnings to ensure safe use.

• Confirm the child is not severely immunocompromised.
• Defer vaccination in individuals with a known severe allergic reaction to any vaccine component.
• Postpone if the child has an acute moderate or severe illness.
• Observe the patient for at least 15 minutes after injection for immediate reactions.
• Discuss pregnancy and breastfeeding status, as safety data are limited.
• Ensure proper storage and handling of the vaccine according to the label.

Havrix Junior may interact with other medicines or vaccines; consider the following guidance.

Avoid

• Concurrent administration with live viral vaccines (e.g., measles, mumps, rubella) within 4 weeks.

Use with caution

• Simultaneous receipt of other inactivated vaccines (e.g., diphtheria‑tetanus‑pertussis) – monitor for increased local reactions.
• Patients receiving immunoglobulins or blood products – may reduce vaccine efficacy.
• Use in children on immunosuppressive therapy – may result in lower antibody response.
• Co‑administration with antipyretics – may mask fever, but does not affect immunogenicity.